Parallax Volatility Advisers
INSY

Parallax Volatility Advisers’s Insys Therapeutics, Inc. INSY Stock Holding History

Parallax Volatility Advisers’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,612
Closed -$35K – 5096
2017
Q4 		$35K Buy
+3,612
New +$23.6K ﹤0.01% 3413

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parallax Volatility Advisers's INSY Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 3,612 shares — an estimated $35K sold.

Parallax Volatility Advisers first reported a position in INSY in Q4 2017 and held it in 1 quarter. The position peaked at $35K in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,612 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $35K.
  • Parallax Volatility Advisers first reported a position in Insys Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Insys Therapeutics, Inc. position peaked at $35K in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.